These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Elevation of extracellular osmolarity improves signs of myotonia congenita in vitro: a preclinical animal study. Hoppe K; Chaiklieng S; Lehmann-Horn F; Jurkat-Rott K; Wearing S; Klingler W J Physiol; 2019 Jan; 597(1):225-235. PubMed ID: 30284249 [TBL] [Abstract][Full Text] [Related]
11. Action potentials reconstructed in normal and myotonic muscle fibres. Adrian RH; Marshall MW J Physiol; 1976 Jun; 258(1):125-43. PubMed ID: 940049 [TBL] [Abstract][Full Text] [Related]
12. Role of physiological ClC-1 Cl- ion channel regulation for the excitability and function of working skeletal muscle. Pedersen TH; Riisager A; de Paoli FV; Chen TY; Nielsen OB J Gen Physiol; 2016 Apr; 147(4):291-308. PubMed ID: 27022190 [TBL] [Abstract][Full Text] [Related]
13. A novel murine myotonia congenita without molecular defects in the ClC-1 and the SCN4A. Shirakawa T; Sakai K; Kitagawa Y; Hori A; Hirose G Neurology; 2002 Oct; 59(7):1091-4. PubMed ID: 12370472 [TBL] [Abstract][Full Text] [Related]
15. Functional characterization of ClC-1 mutations from patients affected by recessive myotonia congenita presenting with different clinical phenotypes. Desaphy JF; Gramegna G; Altamura C; Dinardo MM; Imbrici P; George AL; Modoni A; Lomonaco M; Conte Camerino D Exp Neurol; 2013 Oct; 248():530-40. PubMed ID: 23933576 [TBL] [Abstract][Full Text] [Related]
16. Human sodium channel myotonia: slowed channel inactivation due to substitutions for a glycine within the III-IV linker. Lerche H; Heine R; Pika U; George AL; Mitrovic N; Browatzki M; Weiss T; Rivet-Bastide M; Franke C; Lomonaco M J Physiol; 1993 Oct; 470():13-22. PubMed ID: 8308722 [TBL] [Abstract][Full Text] [Related]
17. A defect in skeletal muscle sodium channel deactivation exacerbates hyperexcitability in human paramyotonia congenita. Featherstone DE; Fujimoto E; Ruben PC J Physiol; 1998 Feb; 506 ( Pt 3)(Pt 3):627-38. PubMed ID: 9503326 [TBL] [Abstract][Full Text] [Related]
18. Safinamide's potential in treating nondystrophic myotonias: Inhibition of skeletal muscle voltage-gated sodium channels and skeletal muscle hyperexcitability in vitro and in vivo. Desaphy JF; Farinato A; Altamura C; De Bellis M; Imbrici P; Tarantino N; Caccia C; Melloni E; Padoani G; Vailati S; Keywood C; Carratù MR; De Luca A; Conte D; Pierno S Exp Neurol; 2020 Jun; 328():113287. PubMed ID: 32205118 [TBL] [Abstract][Full Text] [Related]
19. Preclinical pharmacological in vitro investigations on low chloride conductance myotonia: effects of potassium regulation. Hoppe K; Chaiklieng S; Lehmann-Horn F; Jurkat-Rott K; Wearing S; Klingler W Pflugers Arch; 2020 Oct; 472(10):1481-1494. PubMed ID: 32748018 [TBL] [Abstract][Full Text] [Related]
20. Ranolazine block of human Na v 1.4 sodium channels and paramyotonia congenita mutants. El-Bizri N; Kahlig KM; Shyrock JC; George AL; Belardinelli L; Rajamani S Channels (Austin); 2011; 5(2):161-72. PubMed ID: 21317558 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]